Indegene IPO; Lifesciences company IPO to begin from May 06; Key Details here

Indegene is into Healthcare & Pharmaceuticals Lifesciences and is looking raise funds through Fresh Issue and Offer For Sale

Indegene to raise around Rs 1,842 crores through public issue IPO

Indegene IPO is a public offering of shares by The Company is a professionally managed company and does not have an identifiable promoter.. The IPO will open on May 06 and will close on May 08. The price band is ₹430 to ₹452 per share and the lot size is 33 shares. The issue size is ₹1,841.76 crore. The shares are expected to be listed on NSE, BSE on May 13 (^). Some additional information that you may find useful are: Active clients as on FY23 at 65 (62 in FY22). Business revenues share in 9MFY24 comprises of Income from a) Enterprise commercial solutions at 59.3% (58.9% in FY23) b) Omnichannel activation at 12.1% (12.3% in FY23) c) Enterprise Medical Solutions at 23.0% (24.3% in FY23) d) Others at 5.7% (4.6% in FY23).: (**) - based on higher price band (^) indicative date

Also READ: Bengaluru based Lifesciences Company Indegene files DRHP with SEBI for the proposed IPO; Key Details here

Key Pointers of Indegene IPO:

Promoters of the company are The Company is a professionally managed company and does not have an identifiable promoter. Currently promoters hold 0% stake in the company. While post-equity promoters stake will be .%

Company has not undertaken Pre-IPO placement.

• Company aims to raise between Rs 1,789 to 1,842 crs through this IPO.
• The net proceeds of the issue will be utilized to 1) Repayment / pre=payment of debt of one of the subsidiaries 2) Funding the capex requirements of the company and subsidiaries. and 3) General corporate purpose and inorganic growth.
• Anchor bidding is expected to commence one day prior to the IPO dates. Tentative anchor bidding date would be 03-May-24.
• Price band for the IPO has been fixed at Rs 430 to 452 per share and bid lot are in multiple of 33 shares. The implied market cap post-issue at Rs 10,325 to 10,814 crs.
• As per the tentative schedule, allotment date of this IPO is most likely on May 09 and share are expected to be listed on NSE, BSE on May 13.
• There are no listed companies in India and globally that are of comparable size, from the same industry and with similar business model as that of the Company.
• Kotak Mahindra Capital, Citigroup Global, J.P.Morgan, Nomura Financial has been appointed as Merchant Banker to the issue. Link Intime (India) Pvt. Ltd. has been appointed as official registrar of the issue.

About Indegene Limited

Indegene Limited

Indegene is a digital-first, life sciences commercialization company. Company help biopharmaceutical, emerging biotech, and medical device companies develop products, bring them to market, and enhance their impact throughout the product life cycle. They achieve this through a combination of healthcare domain expertise, fit-for-purpose technology, and an agile operating model. Indegene’s solutions aim to deliver personalized, scalable, and omnichannel experiences for both patients and physicians. With a global team of over 5,000 members across 17 offices, they have earned the trust of 20 out of the top global pharmaceutical companies. As on Q3FY24, company had 65 active clients.

Active clients as on FY23 at 65 (62 in FY22). Business revenues share in 9MFY24 comprises of Income from a) Enterprise commercial solutions at 59.3% (58.9% in FY23) b) Omnichannel activation at 12.1% (12.3% in FY23) c) Enterprise Medical Solutions at 23.0% (24.3% in FY23) d) Others at 5.7% (4.6% in FY23).

Also READ: Aadhar Housing Finance IPO; Housing Finance company IPO to begin from May 08; Key Details here Bharti Hexacom IPO; Telecom Operator company IPO to begin from April 03; Key Details here

About Industry

The life sciences industry primarily comprises biopharmaceutical companies and medical devices companies, whose combined sales were estimated at ₹138.3 trillion (US$1.8 trillion) in 2023, with biopharmaceutical companies constituting 69% or ₹95.4 trillion (US$1.2 trillion) of such sales. Combined sales of biopharmaceutical companies and medical devices companies are estimated to reach ₹163.5 trillion (US$2.1 trillion) by 2026 driven by a rise in aging population, increasing prevalence of chronic diseases and discovery of new diseases, among other factors. Life sciences operations expenditure (which includes spends on marketing and sales, drug discovery and clinical trials, regulatory and medical affairs, manufacturing, supply chain and distribution and pharmacovigilance or complaints management) was estimated at ₹12.0 trillion (US$156 billion) in 2022 and is expected to grow at a CAGR of 6.5% to reach ₹15.5 trillion (US$201 billion) in 2026 in line with growth in industry sales.

Source: SEBI, BSE, NSE, DRHP, IPO Status, Industry Data

Disclaimer: Above article only publishes details about the IPO for educational purpose and doesn't solicit or invite any interest to invest. Please visit respective sources to verify and know more details about the IPO. We advise investors to take opinion from certified/SEBI registered experts before taking any investment decisions.